Cargando…

The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism

Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be enhanced by targeting the unfolded protein response (UPR) kinase, protein kina...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLaughlin, Martin, Pedersen, Malin, Roulstone, Victoria, Bergerhoff, Katharina F., Smith, Henry G., Whittock, Harriet, Kyula, Joan N., Dillon, Magnus T., Pandha, Hardev S., Vile, Richard, Melcher, Alan A., Harrington, Kevin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047134/ https://www.ncbi.nlm.nih.gov/pubmed/32128359 http://dx.doi.org/10.1016/j.omto.2020.01.001

Ejemplares similares

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
por: Twigger, Katie, et al.
Publicado: (2012)

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
por: Annels, Nicola E., et al.
Publicado: (2020)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

GSK2606414 attenuates PERK/p-eIF2α/ATF4/CHOP axis and augments mitochondrial function to mitigate high glucose induced neurotoxicity in N2A cells
por: Gundu, Chayanika, et al.
Publicado: (2022)

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010)

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming
por: Steele, Lynette, et al.
Publicado: (2011)

Reovirus-Mediated Cytotoxicity and Enhancement of Innate Immune Responses Against Acute Myeloid Leukemia
por: Hall, Kathryn, et al.
Publicado: (2012)

Collagenase-Responsive Hydrogel Loaded with GSK2606414 Nanoparticles for Periodontitis Treatment through Inhibiting Inflammation-Induced Expression of PERK of Periodontal Ligament Stem Cells
por: Zhou, Yuchen, et al.
Publicado: (2023)

The Hitchhiker's Guide to Virotherapy
por: Donnelly, Oliver, et al.
Publicado: (2012)

The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors
por: Mahameed, Mohamed, et al.
Publicado: (2019)

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer
por: Mansfield, D C, et al.
Publicado: (2016)

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
por: Bozhanova, Galabina, et al.
Publicado: (2022)

GSK2606414 Sensitizes ABCG2-Overexpressing Multidrug-Resistant Colorectal Cancer Cells to Chemotherapeutic Drugs
por: Yu, Ze-Zhong, et al.
Publicado: (2023)

Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling
por: McEntee, Gráinne, et al.
Publicado: (2016)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020)

Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies
por: Roulstone, Victoria, et al.
Publicado: (2021)

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
por: Jennings, VA, et al.
Publicado: (2014)

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade
por: Patin, Emmanuel C, et al.
Publicado: (2022)

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
por: Simpson, Guy R, et al.
Publicado: (2016)

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status
por: Hafsi, Hind, et al.
Publicado: (2018)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

miRNA-1283 Regulates the PERK/ATF4 Pathway in Vascular Injury by Targeting ATF4
por: He, Ling, et al.
Publicado: (2016)

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?
por: Wongariyapak, Amarin, et al.
Publicado: (2023)

Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
por: Prestwich, Robin J, et al.
Publicado: (2008)

Applications of coxsackievirus A21 in oncology
por: Bradley, Stephen, et al.
Publicado: (2014)

Doxorubicin Induces Cytotoxicity through Upregulation of pERK–Dependent ATF3
por: Park, Eun-Jung, et al.
Publicado: (2012)

Proteostasis in dendritic cells is controlled by the PERK signaling axis independently of ATF4
por: Mendes, Andreia, et al.
Publicado: (2020)

Scleral PERK and ATF6 as targets of myopic axial elongation of mouse eyes
por: Ikeda, Shin-ichi, et al.
Publicado: (2022)

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018)

Emerging Role for the PERK/eIF2α/ATF4 in Human Cutaneous Leishmaniasis
por: Dias-Teixeira, Karina Luiza, et al.
Publicado: (2017)

Activation of the PERK-ATF4 pathway promotes chemo-resistance in colon cancer cells
por: Shi, Zhong, et al.
Publicado: (2019)

Seneca Valley Virus Degrades STING via PERK and ATF6-Mediated Reticulophagy
por: Bai, Ling, et al.
Publicado: (2023)

PERK promotes immunosuppressive M2 macrophage phenotype by metabolic reprogramming and epigenetic modifications through the PERK-ATF4-PSAT1 axis
por: Pratap, Uday P., et al.
Publicado: (2022)

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
por: Ilett, Elizabeth, et al.
Publicado: (2016)

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation
por: McLaughlin, Martin, et al.
Publicado: (2017)

Thbs1 induces lethal cardiac atrophy through PERK-ATF4 regulated autophagy
por: Vanhoutte, Davy, et al.
Publicado: (2021)

PERK/ATF3-Reduced ER Stress on high potassium environment in the suppression of tumor ferroptosis
por: Pu, Xufeng, et al.
Publicado: (2023)

Broad Antigenic Coverage Induced by Viral cDNA Library-based Vaccination Cures Established Tumors
por: Kottke, Timothy, et al.
Publicado: (2011)

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
por: Annels, Nicola E., et al.
Publicado: (2018)

Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells
por: Weng, Shunyan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hopkno65eofmlnsbhd2fqlq2lm